Jump to content

Cediranib: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Arcadian (talk | contribs)
163,050 edits
BogBot (talk | contribs)
Bots
53,132 edits
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot
Line 1: Line 1:
{{drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
⚫
| verifiedrevid = 372183098
⚫
| UNII_Ref = {{fdacite|changed|FDA}}
⚫
| UNII = NQU9IPY4K9| verifiedrevid = 372183098
|
| IUPAC_name = 4-[(4-fluoro-2-methyl-1''H''-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
| IUPAC_name = 4-[(4-fluoro-2-methyl-1''H''-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
| image = AZD2171.svg
| image = AZD2171.svg

<!--Clinical data-->
| tradename =
⚫
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫
| pregnancy_US = <!-- A / B / C / D / X -->
⚫
| pregnancy_category =
⚫
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 -->
⚫
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫
| legal_status =
⚫
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
⚫
| bioavailability =
⚫
| protein_bound =
⚫
| metabolism =
⚫
| elimination_half-life = 12 to 35 hours
⚫
| excretion =

<!--Identifiers-->
| CASNo_Ref = {{cascite}}
| CASNo_Ref = {{cascite}}
| CAS_number =
| CAS_number =
| ATC_prefix = none
| ATC_prefix = none
| ATC_suffix =
| ATC_suffix =
| PubChem =
| PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank =
⚫
| UNII_Ref = {{fdacite|changed|FDA}}
⚫
| C = 25 | H = 27 | F = 1 | N = 4 | O = 3
| UNII = NQU9IPY4K9

<!--Chemical data-->
⚫
| C=25 | H=27 | F=1 | N=4 | O=3
| molecular_weight = 450.505 g/mol
| molecular_weight = 450.505 g/mol
| smiles = Cc4nc5ccc(Oc3ncnc2cc(OCCCN1CCCC1)c(OC)cc23)c(F)c5c4
| smiles = Cc4nc5ccc(Oc3ncnc2cc(OCCCN1CCCC1)c(OC)cc23)c(F)c5c4
⚫
| bioavailability =
⚫
| protein_bound =
⚫
| metabolism =
⚫
| elimination_half-life = 12 to 35 hours
⚫
| excretion =
⚫
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫
| pregnancy_US = <!-- A / B / C / D / X -->
⚫
| pregnancy_category =
⚫
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 -->
⚫
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫
| legal_status =
⚫
| routes_of_administration = Oral
}}
}}
'''Cediranib''' (tentative trade name '''Recentin'''), also known as AZD2171, is a potent [[kinase inhibitor|inhibitor]] of [[vascular endothelial growth factor]] (VEGF) receptor [[tyrosine kinase]]s.<ref name="pmid15899831">{{cite journal |author=Wedge SR, Kendrew J, Hennequin LF, ''et al.'' |title=AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer |journal=Cancer Res. |volume=65 |issue=10 |pages=4389–400 |year=2005 |month=May |pmid=15899831 |doi=10.1158/0008-5472.CAN-04-4409 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=15899831}}</ref><ref name="pmid19091548">{{cite journal |author=Goss G, Shepherd FA, Laurie S, ''et al.'' |title=A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group |journal=Eur. J. Cancer |volume= 45|issue= 5|pages= 782|year=2008 |month=December |pmid=19091548 |doi=10.1016/j.ejca.2008.10.022 |url=http://linkinghub.elsevier.com/retrieve/pii/S0959-8049(08)00868-X}}</ref><ref name="pmid18520296">{{cite journal |author=Nikolinakos P, Heymach JV |title=The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies |journal=J Thorac Oncol |volume=3 |issue=6 Suppl 2 |pages=S131–4 |year=2008 |month=June |pmid=18520296 |doi=10.1097/JTO.0b013e318174e910 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?doi=10.1097/JTO.0b013e318174e910}}</ref>
'''Cediranib''' (tentative trade name '''Recentin'''), also known as AZD2171, is a potent [[kinase inhibitor|inhibitor]] of [[vascular endothelial growth factor]] (VEGF) receptor [[tyrosine kinase]]s.<ref name="pmid15899831">{{cite journal |author=Wedge SR, Kendrew J, Hennequin LF, ''et al.'' |title=AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer |journal=Cancer Res. |volume=65 |issue=10 |pages=4389–400 |year=2005 |month=May |pmid=15899831 |doi=10.1158/0008-5472.CAN-04-4409 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=15899831}}</ref><ref name="pmid19091548">{{cite journal |author=Goss G, Shepherd FA, Laurie S, ''et al.'' |title=A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group |journal=Eur. J. Cancer |volume= 45|issue= 5|pages= 782|year=2008 |month=December |pmid=19091548 |doi=10.1016/j.ejca.2008.10.022 |url=http://linkinghub.elsevier.com/retrieve/pii/S0959-8049(08)00868-X}}</ref><ref name="pmid18520296">{{cite journal |author=Nikolinakos P, Heymach JV |title=The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies |journal=J Thorac Oncol |volume=3 |issue=6 Suppl 2 |pages=S131–4 |year=2008 |month=June |pmid=18520296 |doi=10.1097/JTO.0b013e318174e910 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?doi=10.1097/JTO.0b013e318174e910}}</ref>

Revision as of 23:35, 31 August 2011

Cediranib
Clinical data
Routes of
administration		Oral
ATC code
  • none
Pharmacokinetic data
Elimination half-life12 to 35 hours
Identifiers
  • 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.196.628 Edit this at Wikidata
Chemical and physical data
FormulaC25H27FN4O3
Molar mass450.505 g/mol g·mol−1
3D model (JSmol)
  • Cc4nc5ccc(Oc3ncnc2cc(OCCCN1CCCC1)c(OC)cc23)c(F)c5c4
 ☒NcheckY (what is this?)  (verify)

Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.[1][2][3]

It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.

Beginning in 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.

On February 27, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.

On 8th March 2010, AstraZeneca issued a press-release stating that Recentin had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader Avastin.

References

  1. ^ Wedge SR, Kendrew J, Hennequin LF; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  2. ^ Goss G, Shepherd FA, Laurie S; et al. (2008). "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group". Eur. J. Cancer. 45 (5): 782. doi:10.1016/j.ejca.2008.10.022. PMID 19091548. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  3. ^ Nikolinakos P, Heymach JV (2008). "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies". J Thorac Oncol. 3 (6 Suppl 2): S131–4. doi:10.1097/JTO.0b013e318174e910. PMID 18520296. {{cite journal}}: Unknown parameter |month= ignored (help)

http://www.astrazeneca.com/media/latest-press-releases/2010-new/recoentin-horizon?itemId=8748245

External links


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Cediranib&oldid=447749803"